Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of Denmark’s economic growth.
Prescriptions for a new class of medications used for diabetes and weight loss are concentrated in the city’s wealthier, whiter and healthier neighborhoods.
The empty auditoriums, Gila monsters, resistant pharmaceutical executives and enigmas that led to Ozempic and other drugs that may change how society thinks about obesity.